Sanofi appoints Novartis executive Dr Ameet Nathwani executive VP and CMO
March 10, 2016Medical Communications
Sanofi has announced the appointment of Dr Ameet Nathwani as a new member of its Executive Committee, and to the …
Rigel names Anne-Marie Duliege chief medical officer
March 9, 2016Medical Communications
Biotech firm Rigel Pharmaceuticals (Nasdaq: RIGL) named Anne-Marie Duliege its chief medical officer, replacing Elliott Grossbard, who is retiring.Dr Grossbard will remain …
Shire launches long-acting ADHD drug in UK
March 9, 2016Sales and Marketing ADHD, Shire
Shire has launched its long-acting ADHD drug Intuniv (guanfacine) in the UK, for children and adolescents aged 6-17. The treatment …
Pfizer enters $5 billion share buyback deal with Goldman Sachs
March 9, 2016Business Services, Research and Development Pfizer, Share buyback, Stock, markets
US drug major Pfizer (NYSE: PFE) on Wednesday said it has entered into an accelerated share repurchase agreement with Goldman, …
Pharma industry’s contribution to NHS medicines bill tops £1 billion
March 9, 2016Manufacturing and Production, Medical Communications, Research and Development ABPI, PPRS, goodwill, pharma industry
The pharmaceutical industry has now contributed over £1 billion to the Department of Health towards the cost of new medicines …
Late-stage Pfizer drug study shows significant reduction in haemophilia B bleeding
March 9, 2016Research and Development BeneFIX, Pfizer, haemophilia B
Pfizer on Wednesday said late-stage trials for its drug candidate to treat haemophilia B showed prophylactic use resulted in significant reduction …
TiGenix says additional data for stem cell product affirms safety profile
March 9, 2016Research and Development Crohn’s disease, TiGenix, crohn's disease, drug trial
Belgian biotech firm TiGenix said the results of a 52-week follow-up study of its trial drug for a stem-cell condition …
Merck chief executive Karl-Ludwig Kley to step down in April
March 9, 2016Medical Communications, Research and Development Denreon, Karl-Ludwig Kley, Merck, karl ludwig kley
It has been announced that Karl-Ludwig Kley, chief executive officer at Merck, will step down from his position at the …
French clinical trial tragedy “astonishing and unprecedented”, says report
March 9, 2016Medical Communications, Research and Development Bial, Biotrial, France, clinical trial, death, rennes, tragedy
A report into the clinical trial tragedy in France in January has called the event “astonishing and unprecedented” but did …
Ipsen and PeptiMimesis announce oncology research partnership
March 9, 2016Research and Development INSERM, PeptiMimesis, ipsen, peptides
Specialist pharma company Ipsen is partnering with French start-up PeptiMimesis to develop and market of novel therapeutic peptides in oncology. …
Crown Bioscience expands portfolio with PreClinOmics acquisition
March 9, 2016Manufacturing and Production, Research and Development cardiovascular, collaboration, crown bioscience, metabolic, preclinomics
Crown Bioscience has announced the acquisition of PreClinOmics, which will see the US-based drug discovery solutions company expand its cardiovascular …
MSD joins charity-industry partnership Dementia Consortium
March 9, 2016Medical Communications, Research and Development MSD, alzheimer's society, dementia, dementia consortium
The Dementia Consortium has welcomed MSD into the fold as a new partner in its global venture to accelerate drug …
AZ drug gets orphan status for rare inflammatory disease
March 9, 2016Research and Development AstraZeneca, MEDI-551, MedImmune, orphan drug
AstraZeneca’s biologics R&D arm MedImmune has been granted Orphan Drug Designation by the FDA for its investigational anti-CD19 monoclonal antibody, …
Genmab ends ofatumumab trials for autoimmune conditions; to focus on multiple sclerosis
March 9, 2016Research and Development Arzerra, GSK
Danish drug-company Genmab (Nasdaq Copenhagen: GEN) said it will discontinue the late-stage trials for Arzerra (ofatumumab) to develop a treatment for …
Medimmune gets US FDA fast track designation for flu drug
March 9, 2016Research and Development
UK drug major AstraZeneca (LSE: ANZ) said its biologics R&D unit, MedImmune, has received Fast Track designation from the US …
Groundbreaking Ceremony of SHL Group New Site
March 9, 2016Manufacturing and Production
In Q1 2018, all administrative offices and parts of the production will be relocated to the new site. The ground …
Bayer to collaborate on new treatments for tuberculosis with Universities of Dundee, Cape Town
March 8, 2016Manufacturing and Production, Research and Development Bayer, TB, tuberculosis, university of cape town, university of dundee
The pharmaceuticals division at German-based Bayer will collaborate with the renowned medicinal chemistry and biology departments at the Universities of …
Amgen open to larger M&A deals, says CFO
March 8, 2016Sales and Marketing Amgen, mergers and acquisitions
Amgen’s chief financial officer has indicated that the company is ready to consider doing larger deals to buy other companies, …
Sanofi Pasteur and MSD end European vaccines partnership
March 8, 2016Medical Communications, Research and Development, Sales and Marketing MSD, Sanofi Pasteur, Sanofi pasteur msd, vaccines
Sanofi Pasteur and MSD have announced that they will end their joint vaccines operations in Europe, bringing an end to …
Kuros Biosciences re-appoints chief medical officer
March 8, 2016Medical Communications
Kuros Biosciences has announced the appointment of Dr Virginia Jamieson as chief medical officer and member of the executive board …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
